Subsequent studies have employed antibody-mediated depletion in vivo of γδ T cells and demonstrated protection after depletion of these cells in a breast cancer metastasis model [71], a Kras-driven pancreatic cancer model [72] and a Kras-driven lung cancer model [73]. The gene discussed is KRAS; the disease is breast cancer.